OS Therapies shares rise 11.11% intraday after successful pre-Marketing Authorisation Application Meeting with UK MHRA on Phase 2b OST-HER2 trial.

OS Therapies surged 11.11% intraday following the announcement of a successful pre-Marketing Authorisation Application Meeting with the UK MHRA regarding its Phase 2b clinical trial of OST-HER2. The meeting, a critical step in regulatory approval processes, signals advancing development of the therapy and bolsters investor confidence in the company’s pipeline. The positive news directly aligns with the stock’s intraday rally, reflecting optimism over potential market access for OST-HER2 in the UK.